XY Capital Ltd Acquires 56,306 Shares of Immutep Limited (NASDAQ:IMMP)

XY Capital Ltd increased its holdings in shares of Immutep Limited (NASDAQ:IMMP) by 52.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 164,655 shares of the biotechnology company’s stock after acquiring an additional 56,306 shares during the quarter. Immutep makes up about 0.2% of XY Capital Ltd’s holdings, making the stock its 26th largest position. XY Capital Ltd owned about 0.11% of Immutep worth $357,000 at the end of the most recent quarter.

Separately, Meridian Wealth Management LLC raised its holdings in shares of Immutep by 4.5% in the 3rd quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock worth $881,000 after purchasing an additional 17,250 shares during the period. 2.32% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird boosted their price target on shares of Immutep from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, November 15th.

Immutep Stock Down 0.5 %

Shares of IMMP opened at $2.02 on Monday. The business’s 50-day moving average price is $2.04 and its 200-day moving average price is $2.10. Immutep Limited has a twelve month low of $1.66 and a twelve month high of $3.34. The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01.

Immutep Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.